Effects of teriparatide retreatment in a patient with β-thalassemia major

Transfusion

Volumn 55, Issue 12, 2015, Pages 2905-2910

  Tournis, Symeon ^a   Dede, Anastasia D ^b   Savvidis, Christos ^b   Triantafyllopoulos, Ioannis K ^a   Kattamis, Antonis ^a   Papaioannou, Nikolaos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Department of Endocrinology and Metabolism   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; DEFERIPRONE; DEFEROXAMINE; FERRITIN; PARATHYROID HORMONE[1-34]; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; BACKACHE; BLOOD TRANSFUSION; BONE DENSITY; BONE MASS; CASE REPORT; CHELATION THERAPY; CLINICAL EVALUATION; DRUG EFFECT; FERRITIN BLOOD LEVEL; FOLLOW UP; HUMAN; MALE; OSTEOPOROSIS; PERCUTANEOUS VERTEBROPLASTY; PHYSICAL EXAMINATION; RETREATMENT; SPINE FRACTURE; THALASSEMIA MAJOR; TREATMENT DURATION; TREATMENT RESPONSE; WRIST FRACTURE; BETA-THALASSEMIA; BONE DISEASES; COMPLICATION;

ADULT; ALENDRONATE; BETA-THALASSEMIA; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; HUMANS; MALE; TERIPARATIDE;

EID: 84959559933     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13237     Document Type: Article

References (36)

1. Rund D, Rachmilewitz E., Beta-thalassemia. N Engl J Med 2005; 353: 1135-46.
2. Cooley TB, Lee P,. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr Soc 1925; 37: 29-30.
3. Pasricha SR, Frazer DM, Bowden DK, et al., Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Blood 2013; 122: 124-33.
4. Arnett TR., Acidosis, hypoxia and bone. Arch Biochem Biophys 2010; 503: 103-9.
5. Hiram-Bab S, Liron T, Deshet-Unger N, et al., Erythropoietin directly stimulates osteoclast precursors and induces bone loss. FASEB J 2015; 29: 1890-900.
6. Cappellini MD, Cohen A, Eleftheriou A, et al., Guidelines for the clinical management of thalassaemia. 3rd ed. Cyprus: Thalassemia International Federation.
7. Cazzola M, De Stefano P, Ponchio L, et al., Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol 1995; 89: 473-8.
8. Cazzola M, Borgna-Pignatti C, Locatelli F, et al., A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 1997; 37: 135-40.
9. Baldini M, Forti S, Marcon A, et al., Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. Ann Hematol 2010; 89: 1207-13.
10. Vogiatzi MG, Macklin EA, Fung EB, et al., Prevalence of fractures among the thalassemia syndromes in North America. Bone 2006; 38: 571-5.
11. Vogiatzi MG, Macklin EA, Fung EB, et al., Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 2009; 24: 543-57.
12. Centis F, Tabellini L, Lucarelli G, et al., The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood 2000; 96: 3624-9.
13. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, et al., Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab 2003; 88: 3966-72.
14. Bordat C, Constans A, Bouet O, et al., Iron distribution in thalassemic bone by energy-loss spectroscopy and electron spectroscopic imaging. Calcif Tissue Int 1993; 53: 29-37.
15. De Sanctis V, Soliman AT, Elsedfy H, et al., Growth and endocrine disorders in thalassemia: the international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metab 2013; 17: 8-18.
16. Chan YL, Li CK, Pang LM, et al., Desferrioxamine-induced long bone changes in thalassaemic patients-radiographic features, prevalence and relations with growth. Clin Radiol 2000; 55: 610-4.
17. Voskaridou E, Ladis V, Kattamis A, et al., A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol 2012; 91: 1451-8.
18. Terpos E, Voskaridou E., Treatment options for thalassemia patients with osteoporosis. Ann N Y Acad Sci 2010; 1202: 237-43.
19. Lewiecki EM., Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 2011; 71: 791-814.
20. Cipriani C, Irani D, Bilezikian JP., Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res 2012; 27: 2419-28.
21. Finkelstein JS, Wyland JJ, Leder BZ, et al., Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 2009; 94: 2495-501.
22. Cosman F, Nieves JW, Zion M, et al., Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res 2009; 24: 1110-5.
23. Voskaridou E, Kyrtsonis MC, Terpos E, et al., Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 2001; 112: 36-41.
24. Domrongkitchaiporn S, Sirikulchayanonta V, Angchaisuksiri P, et al., Abnormalities in bone mineral density and bone histology in thalassemia. J Bone Miner Res 2003; 18: 1682-8.
25. Voskaridou E, Christoulas D, Plata E, et al., High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res 2012; 44: 909-13.
26. Voskaridou E, Christoulas D, Xirakia C, et al., Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 2009; 94: 725-8.
27. Ferrari S, Bianchi ML, Eisman JA, et al., Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 2012; 23: 2735-48.
28. Angelopoulos NG, Goula A, Rombopoulos G, et al., Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia. J Bone Miner Metab 2006; 24: 138-45.
29. Chan FK, Tiu SC, Choi KL, et al., Increased bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab 2003; 88: 3155-9.
30. Murad MH, Drake MT, Mullan RJ, et al., Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012; 97: 1871-80.
31. Bellido T, Saini V, Pajevic PD., Effects of PTH on osteocyte function. Bone 2013; 54: 250-7.
32. Trotta A, Corrado A, Cantatore FP., [ Anabolic therapy of induced osteoporosis in beta-thalassaemia major: case report and literature review]. Reumatismo 2010; 62: 119-26.
33. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al., Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008; 23: 1591-600.
34. Eriksen EF, Keaveny TM, Gallagher ER, et al., Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 2014; 67: 246-56.
35. Chen P, Satterwhite JH, Licata AA, et al., Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005; 20: 962-70.
36. Baron R, Hesse E., Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab 2012; 97: 311-25.